- Approval Id
- 193381227e571941
- Drug Approval Emc Name
- Alimemazine Tartrate 10mg Film Coated Tablets
- Drug Name
- Alimemazine Tartrate 10mg Film Coated Tablets
- Company Address
- First Floor, Andrews House, College Road, Guildford, Surrey, GU1 4QB, UK
- Company Website
- https://www.zentiva.co.uk/contact/mi-form
- Company Medical Info Direct Line
- +44 (0)800 090 2408
- Company Medical Info Email
- UKMedInfo@zentiva.com
- Company Customer Care Direct Line
- +44 (0)844 8793 188
- Atc Code
- R06AD01
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Zentiva Pharma UK Limited
12 New Fetter Lane,
London,
EC4A 1JP
United Kingdom
- Authorisation Number
- PL 17780/0464
- Authorisation Date
- 01/08/2009
- Instruction Authorisation Holder
- Zentiva Pharma UK Limited
12 New Fetter Lane,
London,
EC4A 1JP
United Kingdom
- Instruction Authorisation Number
- PL 17780/0464
- Instruction Authorisation Date
- 01/08/2009
- Instruction Composition
- Each film coated tablets contains 10 mg of alimemazine tartrate
\*\*Excipients with known effect:\*\*
Each film coated tablets contains 33.87mg of lactose
For the full list of excipients see section 6.1.
- Instruction Dosage Form
- Film coated tablet
Circular, film coated biconvex tablet with bevelled edge, dark blue in colour, one face impressed V/10. The reverse side is plain.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Alimemazine has a central sedative effect comparable to that of chlorpromazine but largely devoid of the latter's anti adrenaline action.
In children aged 3-7 years:
• Pre-medication sedation before general anaesthesia
Adults and children aged 3 years and over:
• Second-line treatment in the symptomatic relief of urticaria and pruritus.4.2 Posology and method of administration
\*\*Posology\*\*
Not recommended for children less than 3 years old (see also sections 4.3 and 4.4).
DO NOT exceed the recommended dose (see also section 4.9).
\*\*Urticaria and pruritus\*\*
\*Adults:\* 10 mg two or three times daily; up to 100 mg per day have been used in intractable cases.
\*Elderly:\* Dose should be reduced to 10 mg once or twice daily.
\*Children over 3 years of age:\* The use of Alimemazine 7.5 mg/5 ml Syrup is recommended.
\*\*Sedative premedication before general anaesthesia\*\*
\*Children aged 3-7 years\*: the maximum dosage recommended is 2mg per kg bodyweight 1-2 hours before the operation.
This is best achieved using an Alimemazine syrup formulation.
\*\*Method of administration\*\*
The product is administered orally.4.3 Contraindications
Alimemazine is contraindicated in patients with:
• Known hypersensitivity to phenothiazines or to any of the excipients listed in section 6.1.
• Hepatic or renal dysfunction
• Epilepsy
• Parkinson's disease
• Hypothyroidism
• Phaeochromocytoma
• Myasthenia gravis
• History of narrow angle glaucoma
• History of agranulocytosis
• Prostatic hypertrophy.
Alimemazine is contraindicated for use in children less than 3 years of age (see section 4.4).4.4 Special warnings and precautions for use
Patients are strongly advised not to consume alcoholic beverages or medicines containing alcohol throughout treatment (see section 4.5).
Exposure to sunlight should be avoided during treatment (see section 4.8).
\*\*Precautions for use:\*\*
Alimemazine should be used with caution in:
• Elderly or volume depleted patients who are more susceptible to orthostatic hypotension (see section 4.8).
• Elderly patients presenting chronic constipation (risk of paralytic ileus).
• Elderly patients with possible prostatic hypertrophy (see section 4.3).
• Elderly patients in hot and cold weather (risk of hyper/hypothermia) (see section 4.8).
• Patients with certain cardiovascular diseases: alimemazine may cause arrhythmias due to the tachycardia-inducing and hypotensive effects of phenothiazines (see section 4.8).
• Patients with seizures (see section 4.8).
\*\*Paediatric population\*\*
Alimemazine is contraindicated for use in children less than 3 years of age due to the risk of marked sedation and respiratory depression.
There is a risk of post-operative restlessness especially if the child is in pain.
\*\*Lactose\*\*
Patients with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
The sedative effects of phenothiazines may be intensified (additively) by alcohol (see section 4.4), anxiolytics & hypnotics, opiates, barbiturates and other sedatives. There may be increased antimuscarinic and sedative effects of phenothiazines with tricyclic antidepressants & MAOI's (including moclobemide). Respiratory depression may occur.
The hypotensive effect of most antihypertensive drugs especially alpha-adrenoreceptor blocking agents may be exaggerated by phenothiazines. The use of antimuscarinics will increase the risk of antimuscarinic side effects when in conjunction with antihistamines.The action of some drugs may be opposed by phenothiazines; these include amphetamine, levodopa, clonidine, guanethidine and adrenaline.
The mild anticholinergic effect of phenothiazines may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc. Anticholinergic agents may reduce the antipsychotic effect of phenothiazines.
Some drugs interfere with absorption of phenothiazines: antacids, anti-Parkinson and lithium. Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol and phenobarbital have been observed but were not of clinical significance.High doses of phenothiazines reduce the response to hypoglycaemic agents, the dosage of which may have to be raised. Adrenaline must not be used in patients overdosed with phenothiazines.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are limited data from the use of alimemazine tartrate in pregnant women, but it has been widely used for many years without apparent ill consequence. Some phenothiazines have shown evidence of harmful effects in animals. Alimemazine, like other drugs, should be avoided in pregnancy unless the physician considers it essential. Neuroleptics may occasionally prolong labour and at such a time should be withheld until the cervix is dilated 3 – 4 cm. Possible adverse effects on the neonate include lethargy or paradoxical hyperexcitability, tremor and low Apgar score.
\*\*Breast-feeding\*\*
Phenothiazines may be excreted in human milk. Breast-feeding should be discontinued during treatment with alimemazine tartrate.4.7 Effects on ability to drive and use machines
Patients should be warned about drowsiness during the early days of treatment, and advised not to drive or operate machinery.4.8 Undesirable effects
\*\*Gastrointestinal disorders:\*\*
• Constipation
• Dry mouth
\*\*Respiratory, thoracic and mediastinal disorders:\*\*
• Nasal congestion
• Respiratory depression is possible in susceptible patients
\*\*Psychiatric disorders:\*\*
• Insomnia
• Agitation
\*\*Nervous system disorders:\*\*
• Extrapyramidal effects, such as:
- Acute dystonias or dyskinesias, usually transitory are commoner in children and young adults and usually occur within the first 4 days of treatment or after dosage increases.
- Akathisia characteristically occurs after large doses.
- Parkinsonism is commoner in adults and the elderly. It usually develops after weeks or months of treatment. One or more of the following may be seen – tremor, rigidity, akinesia or other features of Parkinsonism (commonly just tremor).
- Tardive dyskinesia. If this occurs it is usually, but not necessarily, after prolonged or high dosage. It can even occur after treatment has been stopped. Dosage should therefore be kept low whenever possible.
• Convulsions have been reported in some patients.
• Dizziness
• Headache
• Drowsiness
\*\*Hepatobiliary disorders:\*\*
Jaundice, usually transient, occurs in a very small percentage of patients. A premonitory sign may be a sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Neuroleptic jaundice has the biochemical and other characteristics of obstructive jaundice and is associated with obstructions of the canaliculi by bile thrombi; the frequent presence of an accompanying eosinophilia indicates the allergic nature of this phenomenon. Treatment should be withheld on the development of jaundice.
\*\*Renal and urinary disorders:\*\*
• Retention of urine
\*\*Vascular disorders:\*\*
• Hypotension or pallor may occur in children.
• Elderly or volume depleted subjects are particularly susceptible to postural hypotension (see section 4.4).
\*\*Cardiac disorders:\*\*
Cardiac arrhythmias including atrial arrhythmia, atrioventricular (A-V) block, ventricular tachycardia and ventricular fibrillation have been reported during therapy, possibly related to dosage (see section 4.4). Pre-existing cardiac disease, old age, hypokalaemia and concurrent tricyclic antidepressants may predispose.
\*\*Investigations:\*\*
Electrocardiogram changes, usually benign, including:
• QT interval prolongation
• U-wave abnormality
• T-wave abnormality
• ST segment depression
\*\*Eye disorders:\*\*
• Accommodation disorders
\*\*Blood and lymphatic system disorders:\*\*
• Mild leukopenia occurs in up to 30% of patients on prolonged high dosage.
• Agranulocytosis may occur rarely; it is not dose related.
The occurrence of unexplained infections or fever requires immediate haematological investigation.
\*\*Skin and subcutaneous tissue disorders:\*\*
• Contact skin sensitisation is a serious but rare complication in those frequently handling preparations of phenothiazines. Care must be taken to avoid contact of the drug with the skin.
• Skin rashes of various kinds may also be seen in patients treated with the drug.
• Patients on high dosage may develop photosensitivity in sunny weather and should avoid exposure to direct sunlight (see section 4.4). Ocular changes and the development of a metallic greyish-mauve colouration of exposed skin have been noted in some individuals, mainly females, who have received chlorpromazine continuously for long periods (four to eight years).
\*\*Endocrine disorders:\*\*
• Hyperprolactinaemia which may result in galactorrhoea, gynaecomastia, amenorrhoea, impotence.
• Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) may occur (see section 4.9).
\*\*General disorders and administration site conditions:\*\*
• Paradoxical excitement has been noted.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Symptoms of phenothiazine overdose include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias and hypothermia.
Severe extra-pyramidal dyskinesias may occur.
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Generalised vasodilatation may result in circulatory collapse; Raising the patient's legs may suffice, in severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.
Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstrictor agents are not generally recommended; avoid the use of adrenaline.
Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life-threatening, appropriate anti-arrhythmic therapy may be considered. Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.
Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions, usually respond to procyclidine (5 – 10 mg) or orphenadrine (20 – 40 mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.
Neuroleptic malignant syndrome (NMS) has been reported in the context of alimemazine overdose. Symptoms of NMS include a combination of hyperthermia, muscle rigidity, altered mental status and autonomic instability. Since this syndrome is potentially fatal, alimemazine must be discontinued immediately, and intensive clinical monitoring and symptomatic treatment must be initiated.
Strict adherence to the recommended dose is critical (see also section 4.2).
Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antihistamines for systemic use, Phenothiazine derivatives, ATC code: R06AD01
Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter's anti-adrenaline action. It has powerful antihistamine and anti-emetic actions.5.2 Pharmacokinetic properties
There is little information about blood levels, distribution and excretion in humans. The rate of metabolism and excretion of phenothiazines decreases in old age.5.3 Preclinical safety data
Not applicable.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Microcrystalline cellulose
Lactose monohydrate (spray dried)
Silica, colloidal anhydrous
Magnesium stearate
Sodium starch glycollate
Hypromellose
Polyethylene glycol 300
Blue opaspray M-1-4229 (purified water EP, Indigo Carmine, Titanium Dioxide, Industrial Methylated Spirits 74 OP BP, Hydroxypropyl methylcellulose)
Purified water6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months6.4 Special precautions for storage
Protect from light. Store below 30 °C.6.5 Nature and contents of container
Securitainer or HDPE bottle containing 50 or 500 tablets.
PVDC coated uPVC/Al foil blister pack containing 28 tablets.6.6 Special precautions for disposal and other handling
Not applicable
- Instruction Content
- ## Composition
Each film coated tablets contains 10 mg of alimemazine tartrate
\*\*Excipients with known effect:\*\*
Each film coated tablets contains 33.87mg of lactose
For the full list of excipients see section 6.1.
## Pharmaceutical Form
Film coated tablet
Circular, film coated biconvex tablet with bevelled edge, dark blue in colour, one face impressed V/10. The reverse side is plain.
## Clinical Particulars
4.1 Therapeutic indications
Alimemazine has a central sedative effect comparable to that of chlorpromazine but largely devoid of the latter's anti adrenaline action.
In children aged 3-7 years:
• Pre-medication sedation before general anaesthesia
Adults and children aged 3 years and over:
• Second-line treatment in the symptomatic relief of urticaria and pruritus.4.2 Posology and method of administration
\*\*Posology\*\*
Not recommended for children less than 3 years old (see also sections 4.3 and 4.4).
DO NOT exceed the recommended dose (see also section 4.9).
\*\*Urticaria and pruritus\*\*
\*Adults:\* 10 mg two or three times daily; up to 100 mg per day have been used in intractable cases.
\*Elderly:\* Dose should be reduced to 10 mg once or twice daily.
\*Children over 3 years of age:\* The use of Alimemazine 7.5 mg/5 ml Syrup is recommended.
\*\*Sedative premedication before general anaesthesia\*\*
\*Children aged 3-7 years\*: the maximum dosage recommended is 2mg per kg bodyweight 1-2 hours before the operation.
This is best achieved using an Alimemazine syrup formulation.
\*\*Method of administration\*\*
The product is administered orally.4.3 Contraindications
Alimemazine is contraindicated in patients with:
• Known hypersensitivity to phenothiazines or to any of the excipients listed in section 6.1.
• Hepatic or renal dysfunction
• Epilepsy
• Parkinson's disease
• Hypothyroidism
• Phaeochromocytoma
• Myasthenia gravis
• History of narrow angle glaucoma
• History of agranulocytosis
• Prostatic hypertrophy.
Alimemazine is contraindicated for use in children less than 3 years of age (see section 4.4).4.4 Special warnings and precautions for use
Patients are strongly advised not to consume alcoholic beverages or medicines containing alcohol throughout treatment (see section 4.5).
Exposure to sunlight should be avoided during treatment (see section 4.8).
\*\*Precautions for use:\*\*
Alimemazine should be used with caution in:
• Elderly or volume depleted patients who are more susceptible to orthostatic hypotension (see section 4.8).
• Elderly patients presenting chronic constipation (risk of paralytic ileus).
• Elderly patients with possible prostatic hypertrophy (see section 4.3).
• Elderly patients in hot and cold weather (risk of hyper/hypothermia) (see section 4.8).
• Patients with certain cardiovascular diseases: alimemazine may cause arrhythmias due to the tachycardia-inducing and hypotensive effects of phenothiazines (see section 4.8).
• Patients with seizures (see section 4.8).
\*\*Paediatric population\*\*
Alimemazine is contraindicated for use in children less than 3 years of age due to the risk of marked sedation and respiratory depression.
There is a risk of post-operative restlessness especially if the child is in pain.
\*\*Lactose\*\*
Patients with rare hereditary problems of galactose intolerance, total lactose deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
The sedative effects of phenothiazines may be intensified (additively) by alcohol (see section 4.4), anxiolytics & hypnotics, opiates, barbiturates and other sedatives. There may be increased antimuscarinic and sedative effects of phenothiazines with tricyclic antidepressants & MAOI's (including moclobemide). Respiratory depression may occur.
The hypotensive effect of most antihypertensive drugs especially alpha-adrenoreceptor blocking agents may be exaggerated by phenothiazines. The use of antimuscarinics will increase the risk of antimuscarinic side effects when in conjunction with antihistamines.The action of some drugs may be opposed by phenothiazines; these include amphetamine, levodopa, clonidine, guanethidine and adrenaline.
The mild anticholinergic effect of phenothiazines may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc. Anticholinergic agents may reduce the antipsychotic effect of phenothiazines.
Some drugs interfere with absorption of phenothiazines: antacids, anti-Parkinson and lithium. Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol and phenobarbital have been observed but were not of clinical significance.High doses of phenothiazines reduce the response to hypoglycaemic agents, the dosage of which may have to be raised. Adrenaline must not be used in patients overdosed with phenothiazines.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are limited data from the use of alimemazine tartrate in pregnant women, but it has been widely used for many years without apparent ill consequence. Some phenothiazines have shown evidence of harmful effects in animals. Alimemazine, like other drugs, should be avoided in pregnancy unless the physician considers it essential. Neuroleptics may occasionally prolong labour and at such a time should be withheld until the cervix is dilated 3 – 4 cm. Possible adverse effects on the neonate include lethargy or paradoxical hyperexcitability, tremor and low Apgar score.
\*\*Breast-feeding\*\*
Phenothiazines may be excreted in human milk. Breast-feeding should be discontinued during treatment with alimemazine tartrate.4.7 Effects on ability to drive and use machines
Patients should be warned about drowsiness during the early days of treatment, and advised not to drive or operate machinery.4.8 Undesirable effects
\*\*Gastrointestinal disorders:\*\*
• Constipation
• Dry mouth
\*\*Respiratory, thoracic and mediastinal disorders:\*\*
• Nasal congestion
• Respiratory depression is possible in susceptible patients
\*\*Psychiatric disorders:\*\*
• Insomnia
• Agitation
\*\*Nervous system disorders:\*\*
• Extrapyramidal effects, such as:
- Acute dystonias or dyskinesias, usually transitory are commoner in children and young adults and usually occur within the first 4 days of treatment or after dosage increases.
- Akathisia characteristically occurs after large doses.
- Parkinsonism is commoner in adults and the elderly. It usually develops after weeks or months of treatment. One or more of the following may be seen – tremor, rigidity, akinesia or other features of Parkinsonism (commonly just tremor).
- Tardive dyskinesia. If this occurs it is usually, but not necessarily, after prolonged or high dosage. It can even occur after treatment has been stopped. Dosage should therefore be kept low whenever possible.
• Convulsions have been reported in some patients.
• Dizziness
• Headache
• Drowsiness
\*\*Hepatobiliary disorders:\*\*
Jaundice, usually transient, occurs in a very small percentage of patients. A premonitory sign may be a sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Neuroleptic jaundice has the biochemical and other characteristics of obstructive jaundice and is associated with obstructions of the canaliculi by bile thrombi; the frequent presence of an accompanying eosinophilia indicates the allergic nature of this phenomenon. Treatment should be withheld on the development of jaundice.
\*\*Renal and urinary disorders:\*\*
• Retention of urine
\*\*Vascular disorders:\*\*
• Hypotension or pallor may occur in children.
• Elderly or volume depleted subjects are particularly susceptible to postural hypotension (see section 4.4).
\*\*Cardiac disorders:\*\*
Cardiac arrhythmias including atrial arrhythmia, atrioventricular (A-V) block, ventricular tachycardia and ventricular fibrillation have been reported during therapy, possibly related to dosage (see section 4.4). Pre-existing cardiac disease, old age, hypokalaemia and concurrent tricyclic antidepressants may predispose.
\*\*Investigations:\*\*
Electrocardiogram changes, usually benign, including:
• QT interval prolongation
• U-wave abnormality
• T-wave abnormality
• ST segment depression
\*\*Eye disorders:\*\*
• Accommodation disorders
\*\*Blood and lymphatic system disorders:\*\*
• Mild leukopenia occurs in up to 30% of patients on prolonged high dosage.
• Agranulocytosis may occur rarely; it is not dose related.
The occurrence of unexplained infections or fever requires immediate haematological investigation.
\*\*Skin and subcutaneous tissue disorders:\*\*
• Contact skin sensitisation is a serious but rare complication in those frequently handling preparations of phenothiazines. Care must be taken to avoid contact of the drug with the skin.
• Skin rashes of various kinds may also be seen in patients treated with the drug.
• Patients on high dosage may develop photosensitivity in sunny weather and should avoid exposure to direct sunlight (see section 4.4). Ocular changes and the development of a metallic greyish-mauve colouration of exposed skin have been noted in some individuals, mainly females, who have received chlorpromazine continuously for long periods (four to eight years).
\*\*Endocrine disorders:\*\*
• Hyperprolactinaemia which may result in galactorrhoea, gynaecomastia, amenorrhoea, impotence.
• Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) may occur (see section 4.9).
\*\*General disorders and administration site conditions:\*\*
• Paradoxical excitement has been noted.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Symptoms of phenothiazine overdose include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias and hypothermia.
Severe extra-pyramidal dyskinesias may occur.
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Generalised vasodilatation may result in circulatory collapse; Raising the patient's legs may suffice, in severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.
Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstrictor agents are not generally recommended; avoid the use of adrenaline.
Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life-threatening, appropriate anti-arrhythmic therapy may be considered. Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.
Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions, usually respond to procyclidine (5 – 10 mg) or orphenadrine (20 – 40 mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.
Neuroleptic malignant syndrome (NMS) has been reported in the context of alimemazine overdose. Symptoms of NMS include a combination of hyperthermia, muscle rigidity, altered mental status and autonomic instability. Since this syndrome is potentially fatal, alimemazine must be discontinued immediately, and intensive clinical monitoring and symptomatic treatment must be initiated.
Strict adherence to the recommended dose is critical (see also section 4.2).
Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antihistamines for systemic use, Phenothiazine derivatives, ATC code: R06AD01
Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter's anti-adrenaline action. It has powerful antihistamine and anti-emetic actions.5.2 Pharmacokinetic properties
There is little information about blood levels, distribution and excretion in humans. The rate of metabolism and excretion of phenothiazines decreases in old age.5.3 Preclinical safety data
Not applicable.
## Pharmaceutical Particulars
6.1 List of excipients
Microcrystalline cellulose
Lactose monohydrate (spray dried)
Silica, colloidal anhydrous
Magnesium stearate
Sodium starch glycollate
Hypromellose
Polyethylene glycol 300
Blue opaspray M-1-4229 (purified water EP, Indigo Carmine, Titanium Dioxide, Industrial Methylated Spirits 74 OP BP, Hydroxypropyl methylcellulose)
Purified water6.2 Incompatibilities
Not applicable.6.3 Shelf life
36 months6.4 Special precautions for storage
Protect from light. Store below 30 °C.6.5 Nature and contents of container
Securitainer or HDPE bottle containing 50 or 500 tablets.
PVDC coated uPVC/Al foil blister pack containing 28 tablets.6.6 Special precautions for disposal and other handling
Not applicable
- Company Detail Path
- /organization/sanofi-ilac-sanayi-ve-ticaret-anonim-sirketi
